The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Silver47 Exploration
AGA:CC
Purpose Bitcoin ETF
BTCC:CA
Jindalee Lithium
JLL:AU
Black Swan Graphene
SWAN:CC
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Insulet Corporation (NASDAQ:PODD), which has a tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced an agreement with Amgen Inc. (NASDAQ:AMGN) for a 5-year commercial agreement to supply Amgen with a delivery device designed around the delivery needs of biotechnology medicines.
Insulet Corporation (NASDAQ:PODD), which has a tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced an agreement with Amgen Inc. (NASDAQ:AMGN) for a 5-year commercial agreement to supply Amgen with a delivery device designed around the delivery needs of biotechnology medicines.
As quoted in the market news:
“We are thrilled to advance our collaboration with Amgen to supply this version of our technology,” said Duane DeSisto, President and Chief Executive Officer of Insulet.
DeSisto added that “Insulet’s current device, the OmniPod®, is a unique drug delivery platform that provides the ability to vary rate at which medication is infused. With over 25 million OmniPods produced, our innovative product is the undisputed global leader in patch pump technology and provides a patient-friendly and cost effective drug delivery alternative.”
Read the full news release by Insulet Corporation (NASDAQ:PODD)
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.